BioMarin slides as higher 2026 revenue outlook comes with lower EPS guidance
BioMarin shares fell as investors digested Q1 2026 results and updated full-year guidance issued on May 4, 2026. While revenue guidance rose to $3.825–$3.925 billion after the Amicus deal closed, adjusted EPS guidance was cut to $4.85–$5.05, weighing on the stock.
1. What’s moving the stock
BioMarin (BMRN) is down about 3.25% to $53.65 as the market reprices the company’s updated 2026 outlook following its May 4, 2026 first-quarter earnings release and call. The key pressure point is that BioMarin lifted full-year revenue guidance after adding Amicus products, but simultaneously reduced adjusted earnings-per-share guidance, signaling near-term margin and cost headwinds even as the top-line trajectory improves. (investors.biomarin.com)
2. The numbers investors are reacting to
BioMarin’s updated 2026 revenue guidance rose to $3.825–$3.925 billion, reflecting the inclusion of Amicus and implying faster year-over-year growth at the consolidated level. However, BioMarin’s adjusted EPS guidance moved down to $4.85–$5.05 versus the prior range, reinforcing concerns that integration expenses, transaction-related items, and mix/margin effects may outweigh the near-term benefit of the larger revenue base. (uk.investing.com)
3. Analyst and positioning backdrop
After the guidance update, at least one major sell-side firm lowered its price target, highlighting that the market’s debate is shifting from “growth added via acquisition” to “how quickly that growth converts into earnings.” With BioMarin shares already trading under pressure, incremental skepticism on margins and the timing of earnings realization can translate into a sharper one-day move even without a single negative clinical or regulatory headline. (uk.investing.com)